November 14, 2022
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
November 4, 2022
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
October 31, 2022
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
October 27, 2022
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
October 26, 2022
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
October 13, 2022
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
October 5, 2022
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
August 26, 2022
Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
August 15, 2022
Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
August 15, 2022
Sema4 Announces Changes to its Research & Development Leadership
Displaying 1 - 10 of 30